Prophylactic Administration with Methylene Blue Improves Hemodynamic Stabilization During Obstructive Jaundice–Related Diseases’ Operation: a Blinded Randomized Controlled Trial

Jian Huang, Xian Gao, Moran Wang, Zhen Yang, Lunli Xiang, Yongshuai Li, Yi Bin, Jianteng Gu, Jing Wen, Kaizhi Lu, Hongwen Zhao, Daqing Ma, Li Chen, Jiaolin NingJournal of Gastrointestinal Surgery 2023 · DOI

TL;DR

A blinded randomized controlled trial demonstrates that a prophylactic dose of methylene blue significantly improves hemodynamic stability in patients undergoing surgery for obstructive jaundice. By inhibiting excess nitric oxide, methylene blue reduces the need for high-dose vasopressors and protects liver and kidney function, ultimately shortening ICU stays.

What Problem Does This Paper Address?

Patients with obstructive jaundice (where bile flow is blocked) are a high-risk surgical population. The condition leads to a systemic accumulation of bilirubin and bile acids, which triggers an overproduction of nitric oxide (NO). This excess NO causes systemic vasodilation—essentially making blood vessels too relaxed—leading to severe hypotension (low blood pressure) once anesthesia is induced.

To keep these patients stable, clinicians often have to "flood" them with fluids and high doses of catecholamines like noradrenaline. However, high-dose vasopressors are a double-edged sword: they can cause excessive vasoconstriction in the micro-circulation, leading to organ damage and higher mortality. This paper investigates whether preemptively blocking the NO pathway with methylene blue can prevent this "hemodynamic crash" before it starts.

Methods

The researchers conducted a prospective, blinded, randomized controlled trial (RCT) at Southwest Hospital in Chongqing, China.

  • Participants: 70 patients with obstructive jaundice (Total Bilirubin > 5.0 mg/ml) scheduled for surgery.
  • Intervention: The treatment group received a prophylactic dose of 2 mg/kg methylene blue (MB) in saline before anesthesia induction. The control group received a volume-matched saline placebo.
  • Standardization: Both groups followed a strict, identical anesthesia and fluid management protocol. Hemodynamics were monitored invasively via arterial catheters and Swan-Ganz catheters to measure systemic vascular resistance (SVR) and cardiac output (CO).
  • Blinding: Both the data collectors and the anesthesiologists performing the procedures were blinded to the group assignments.

Datasets

As a clinical trial, the "dataset" consists of the clinical and biochemical profiles of the 70 enrolled patients (35 per group).

  • Baseline: Groups were well-matched for age, BMI, and etiology (e.g., cholangiocarcinoma, gallbladder carcinoma).
  • Primary Outcome: Frequency and total dose of noradrenaline required to maintain a mean arterial pressure (MAP) > 65 mmHg.
  • Secondary Outcomes: Post-operative liver/kidney function markers and length of ICU/hospital stay.

Key Insights and Ideas

  • The Nitric Oxide Connection: The study reinforces the theory that the "vaso-hypotonia" seen in jaundice is driven by the NO pathway. Methylene blue acts as a potent inhibitor of nitric oxide synthase (NOS) and guanylate cyclase, effectively "tightening" the relaxed vasculature.
  • Prophylaxis vs. Rescue: While methylene blue is often used as a "last resort" for refractory shock (e.g., in cardiac surgery or sepsis), this study suggests that early, prophylactic administration is more effective. By preventing the initial drop in vascular resistance, clinicians avoid the "catch-up" game of high-dose vasopressors.
  • Beyond Blood Pressure: The most striking insight is that hemodynamic stability translates directly to organ protection. The MB group didn't just have better blood pressure; they had significantly lower markers of muscle, liver, and kidney damage post-surgery.

Key Results

The prophylactic administration of methylene blue led to superior outcomes across nearly all primary metrics:

  • Reduced Vasopressor Need: Only 37% of the MB group required noradrenaline, compared to 63% in the control group ($P=0.017$).
  • Lower Dosing: Only 3% of the MB group needed a high total dose (>2 mg) of noradrenaline, versus 26% of the control group ($P=0.006$).
  • Organ Protection: Post-operative levels of creatinine (kidney), GOT/GPT (liver), and Creatine Kinase (muscle/heart) were significantly lower in the MB group on days 1, 2, and 3.
  • Faster Recovery: The MB group had a significantly shorter ICU stay (2.5 days vs. 3.4 days, $P=0.013$).

Limitations and Future Work

The authors acknowledge several constraints that warrant caution:

  • Sample Size: With only 70 patients from a single center, the study may not capture rarer side effects or broader population variances.
  • Measurement Interference: Methylene blue is a dye that can interfere with pulse oximetry readings (making oxygen saturation appear lower than it is) and turns urine blue/green, which requires clinical vigilance.
  • Long-term Outcomes: The study focused on short-term prognosis and peri-operative stability; the impact on 6-month or 1-year survival remains unclear (though mortality was slightly lower in the MB group, it wasn't statistically significant in this small sample).
  • Future Directions: Larger multi-center trials are needed to confirm these findings and to determine if MB benefits patients with lower-risk profiles or different types of liver disease.

Summary updated

Abstract

Methylene blue is a promising and recommended drug for the patients undergoing the surgeries of relief obstructive jaundice during peri-operation management.
BibTeX
@article{huang2023prophylactic,
  author = {Jian Huang and Xian Gao and Moran Wang and Zhen Yang and Lunli Xiang and Yongshuai Li and Yi Bin and Jianteng Gu and Jing Wen and Kaizhi Lu and Hongwen Zhao and Daqing Ma and Li Chen and Jiaolin Ning},
  title = {{Prophylactic Administration with Methylene Blue Improves Hemodynamic Stabilization During Obstructive Jaundice–Related Diseases’ Operation: a Blinded Randomized Controlled Trial}},
  journal = {Journal of Gastrointestinal Surgery},
  year = {2023},
  doi = {10.1007/s11605-022-05499-3},
}
Figure